TriSalus Life Sciences, Inc. Share Price & Technical Analysis
TLSI · $3.15 (-3.37%)
Healthcare / Medical Devices
$3.15
-3.37%
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial …
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-25% return in May, -8% avg return in past 3 year May month.
-64% return in 2026, 13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -29% | 2% | -20% | 8% | -25% | – | – | – | – | – | – | – | -64% |
| 25 | 2% | 9% | -4% | -7% | -2% | 8% | -21% | 24% | -10% | 2% | 44% | 3% | 49% |
| 24 | 10% | 6% | 3% | -5% | -24% | -24% | 2% | -9% | -10% | -13% | 18% | 11% | -35% |
| 23 | 1% | 0% | 1% | -1% | 2% | 1% | -7% | -35% | -23% | -14% | -17% | 115% | 24% |
| 22 | 0% | 0% | -2% | 0% | -1% | 0% | 1% | 0% | 0% | 1% | 1% | -1% | -1% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$283.12M
P/E ratio
—
52W high
$7.95
52W low
$2.20
Volume
1,40,563
Beta
0.56
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is TriSalus Life Sciences, Inc. share price today?
- TriSalus Life Sciences, Inc. (TLSI) last traded around $3.15 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TLSI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TLSI. Download the app for real-time alerts.
- How can I analyze TriSalus Life Sciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.